NICE vs RCEM: Management of Acute Kidney Injury (2025)
Acute Kidney Injury (AKI) is a common and serious clinical problem encountered across primary care, medical wards, and the emergency department. In the UK, clinicians primarily refer to two key national guidelines: the National Institute for Health and Care Excellence (NICE) Clinical Guideline CG148 (published 2013, updated 2019) and the Royal College of Emergency Medicine (RCEM) Guideline for the Management of Acute Kidney Injury in the Emergency Department (2022). While both aim to improve patient outcomes, their scope, focus, and practical recommendations differ significantly. This comparison provides a factual analysis for clinicians, highlighting key differences and practical takeaways for UK practice.
See how this translates to practice: Explore our Clinical governance features, visit the Patient Safety Hub, or review Clinical Safety & Assurance for enterprise rollout.
Fundamental Distinction: The NICE guideline provides a comprehensive, hospital-wide framework for AKI management applicable to all healthcare settings. In contrast, the RCEM guideline offers a specialised, time-critical pathway specifically designed for the initial assessment, resuscitation, and disposition decisions within the Emergency Department (ED).
Diagnosis and Assessment
NICE CG148
NICE bases the diagnosis and staging of AKI on the KDIGO (Kidney Disease: Improving Global Outcomes) criteria, using changes in serum creatinine (sCr) and urine output. This is the universal standard in the UK.
- Diagnosis: A rise in sCr ≥ 26.5 μmol/L within 48 hours or a 1.5-fold increase from baseline known or presumed to have occurred within the last 7 days.
- Staging: Stages 1, 2, and 3 based on the magnitude of sCr increase or reduction in urine output.
- Assessment: Emphasises a thorough history to identify cause, including medication review (especially NSAIDs, ACE inhibitors, diuretics), assessment of volume status, and investigation for obstruction.
- Key Tool: Recommends the use of an AKI care bundle for all patients with AKI, which includes specific actions to be completed within 24 hours of detection.
RCEM Guideline
RCEM fully adopts the KDIGO/NICE diagnostic criteria but reframes the assessment for the ED context, focusing on immediate life threats and disposition.
- Pragmatic Staging: While it acknowledges formal staging, RCEM introduces a more practical ED classification: "Community-Acquired AKI" (presenting to ED with AKI) vs. "Hospital-Acquired AKI" (developing AKI while an inpatient). This distinction helps frame the initial diagnostic approach.
- Focus on "The Four D's": The cornerstone of the RCEM assessment is identifying:
- Drugs (nephrotoxins)
- Dehydration (pre-renal)
- Disease (intrinsic renal, e.g., glomerulonephritis)
- Drainage (post-renal obstruction)
- Key Tool: Promotes the use of a dedicated AKI proforma integrated into the ED notes to standardise assessment and ensure key actions (e.g., fluid challenges, catheterisation, specific blood tests) are not missed.
Key Difference: NICE provides the diagnostic standard and a systematic approach for ongoing management. RCEM provides an ED-specific, rapid triage framework ("The Four D's") to quickly identify reversible causes and guide immediate treatment.
Treatment and Management
NICE CG148
NICE's treatment recommendations are broad, focusing on correcting the underlying cause and providing supportive care.
- Fluid Resuscitation: Recommends IV fluid therapy for patients with AKI and volume depletion. Crystalloids are the fluid of choice.
- Medication Management: Strong emphasis on stopping nephrotoxic drugs (e.g., NSAIDs, aminoglycosides) and reviewing drugs that affect renal perfusion (e.g., ACEi/ARBs, diuretics).
- Monitoring: Recommends close monitoring of serum creatinine, electrolytes, and urine output.
- Referral: Advises referral to nephrology for patients with AKI Stage 3 or those with a progressive rise in creatinine.
- Prevention: Includes guidance on preventing AKI in community and hospital settings, particularly before IV contrast and in high-risk surgical patients.
RCEM Guideline
RCEM's treatment advice is targeted at the first 4-6 hours of care in the ED, with a strong focus on resuscitation and making a safe disposition decision.
- Aggressive Fluid Challenges: Strongly advocates for prompt, measured fluid challenges (e.g., 250-500ml boluses) for patients with suspected pre-renal AKI, with reassessment after each bolus. The goal is to achieve clinical euvolaemia rapidly.
- Urinary Catheterisation: Recommends early catheterisation for accurate monitoring of urine output and for relief of suspected obstruction. This is a more proactive stance than NICE.
- Hyperkalaemia: Provides a clear, immediate management pathway for life-threatening hyperkalaemia, including the use of insulin-dextrose, salbutamol, and calcium gluconate.
- Disposition Focus: The primary treatment goal in the ED is to determine if the patient requires admission. RCEM provides clear criteria for admission (e.g., AKI Stage 2/3, significant comorbidities, failure to respond to initial fluid resuscitation) vs. potential for discharge with close follow-up (e.g., mild, pre-renal AKI Stage 1 that has responded well to treatment).
Key Difference: NICE outlines the principles of general AKI management. RCEM is more interventionist and time-pressured, emphasising rapid fluid challenges, proactive catheterisation, and a clear exit strategy from the ED (admit or discharge).
Special Situations
NICE CG148
- Contrast-Induced AKI (CI-AKI): Provides specific recommendations for risk assessment and prevention with IV fluids in high-risk patients undergoing radiological studies.
- Rhabdomyolysis: Advises early, aggressive volume resuscitation with IV fluids.
- Obstruction: Recommends urgent imaging (ultrasound) and urological referral for relief of obstruction.
RCEM Guideline
- Sepsis-Induced AKI: This is a major focus. Management is fully integrated into the Sepsis Six pathway, emphasising immediate antibiotics and fluid resuscitation.
- Cardiorenal Syndrome: Provides specific guidance on managing AKI in the patient with heart failure, a common ED dilemma. It advises cautious fluid challenges with close monitoring for signs of pulmonary oedema and early senior review.
- End-of-Life Care: Acknowledges that for some patients with advanced comorbidities, aggressive AKI management may not be appropriate. Recommends early consideration of palliative care pathways and "ceilings of care" discussions in the ED.
Key Difference: NICE covers a wider range of causative situations. RCEM delves deeper into the complex, high-stakes scenarios most relevant to emergency physicians, particularly sepsis and the cardiorenal syndrome.
Practical Clinical Flow: An Integrated View
For a clinician in the ED, integrating both guidelines creates a robust pathway:
- Identification: AKI is flagged by an alert from the laboratory or noted on blood results.
- Immediate Assessment (RCEM): Apply the "Four D's" framework. Take a focused history (Drugs), assess volume status (Dehydration), look for signs of intrinsic disease (Disease, e.g., rash, haematuria), and check for a palpable bladder or history of prostatism (Drainage).
- Resuscitation & Initial Treatment (RCEM):
- Manage life-threatening hyperkalaemia.
- Commence fluid challenges if hypovolaemic.
- Catheterise if indicated for monitoring or suspected obstruction.
- Stop nephrotoxic drugs.
- Investigation & Staging (NICE/RCEM): Send bloods (including FBC, U&E, CRP, VBG), urine dipstick, and formalise the AKI stage using KDIGO criteria.
- Disposition Decision (RCEM): Based on response to treatment, AKI stage, and comorbidities, decide to admit or discharge. For discharge, ensure clear safety-netting: follow-up within 48 hours, written advice, and medication review.
- Ongoing Inpatient Management (NICE): If admitted, the NICE AKI care bundle should be initiated to ensure comprehensive management, including nephrology referral if appropriate.
Frequently Asked Questions (FAQs)
1. Which guideline should I follow in the Emergency Department?
Answer: Primarily follow the RCEM guideline for the initial ED management. It is specifically designed for the time-critical, decision-focused environment of the ED. The NICE guideline provides the overarching diagnostic standard and is more relevant for ongoing inpatient care.
2. A patient with AKI Stage 1 has responded well to a fluid challenge. Can they be discharged?
Answer: According to RCEM, yes, this can be considered, provided the cause is clearly reversible (e.g., dehydration), the patient has no significant comorbidities, and there is a robust follow-up plan in place (e.g., GP review in 48 hours, repeat U&E). This is a key practical difference from a default admission pathway.
3. Should I stop ACE inhibitors/ARBs in all patients with AKI?
Answer: Both guidelines recommend reviewing these drugs. In a patient with hypovolaemia, they should almost always be stopped temporarily. However, in a euvolaemic or hypervolaemic patient (e.g., with heart failure), the decision is more complex and may require senior input. RCEM emphasises this nuance in the context of cardiorenal syndrome.
4. How quickly should I refer to nephrology?
Answer: NICE recommends referral for AKI Stage 3. In practice, discuss with nephrology early if there is suspicion for a rapidly progressive glomerulonephritis (RPGN), signs of systemic disease, or if the cause is unclear and the patient is deteriorating despite initial management.
5. What is the single most important practical takeaway from the RCEM guideline?
Answer: The "Four D's" (Drugs, Dehydration, Disease, Drainage) framework. This simple, memorable tool ensures a systematic assessment of the most common and reversible causes of AKI in the ED, preventing diagnostic oversight.
Source Links
- NICE Guideline CG148 (Acute kidney injury: prevention, detection and management): NICE CG148 (Published August 2013, Last updated October 2019)
- Royal College of Emergency Medicine (RCEM) Guideline: Guideline for the Management of Acute Kidney Injury in the Emergency Department (Published September 2022)